Skip to content

Dopamine in Neonate

Pharmacokinetic and Pharmacodynamic Study of Sildenafil in Neonates and Preterm Infants

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04525495
Enrollment
30
Registered
2020-08-25
Start date
2020-04-01
Completion date
2022-12-31
Last updated
2020-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonates and Preterm Infants

Brief summary

The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of dopamine which is used as treatment of hypotension in neonate and preterm infant.

Interventions

DRUGDopamine

Dopamine treatment

Sponsors

Asan Medical Center
CollaboratorOTHER
Severance Hospital
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Months
Healthy volunteers
No

Inclusion criteria

* Admitted at NICU in Seoul National University Hospital, Seoul Asan Hospital or Severance Hospital * Infants who were diagnosed with hypotension

Exclusion criteria

* Congenital heart disease * Chromosomal anomaly * Treated with ECMO or CRRT * Arrhythmia * Hypovolemic state

Design outcomes

Primary

MeasureTime frameDescription
Steady state concentration of dopamine (Css) at 2mcg/kg/minAfter continuous infusion for more than 30 minutes at 2mcg/kg/mindopamine drug level in blood
Steady state concentration of dopamine (Css) at 5mcg/kg/minAfter continuous infusion for more than 30 minutes at 5mcg/kg/mindopamine drug level in blood
Steady state concentration of dopamine (Css) at 10mcg/kg/minAfter continuous infusion for more than 30 minutes at 10mcg/kg/mindopamine drug level in blood
Steady state concentration of dopamine (Css) at 15mcg/kg/minAfter continuous infusion for more than 30 minutes at 15mcg/kg/mindopamine drug level in blood
Steady state concentration of dopamine (Css) at 20mcg/kg/minAfter continuous infusion for more than 30 minutes at 20mcg/kg/mindopamine drug level in blood

Secondary

MeasureTime frameDescription
Fractional shortening from EchocardiographyAfter continuous infusion for more than 30 minutes at 2mcg/kg/min
Blood pressure in mmHg at 2mcg/kg/minAfter continuous infusion for more than 30 minutes at 2mcg/kg/minSystolic, diastolic and mean blood pressure in mmHg
VTI (velocity time integral) from EchocardiographyAfter continuous infusion for more than 30 minutes at 2mcg/kg/minthe area within the spectral curve and indicates how far blood travels during the flow period
Tei index from EchocardiographyAfter continuous infusion for more than 30 minutes at 2mcg/kg/min(Mitral valve closure to opening time(ms)-LV ejection time(ms))/LV ejection time(ms)
Blood pressure in mmHg at 5mcg/kg/minAfter continuous infusion for more than 30 minutes at 5mcg/kg/minSystolic, diastolic and mean blood pressure in mmHg
Blood pressure in mmHg at 10mcg/kg/minAfter continuous infusion for more than 30 minutes at 10mcg/kg/minSystolic, diastolic and mean blood pressure in mmHg
Heart rateAfter continuous infusion for more than 30 minutes at 2mcg/kg/min
Ejection fraction from EchocardiographyAfter continuous infusion for more than 30 minutes at 2mcg/kg/min

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026